Johnson & Johnson (JNJ) Stock
Diversified healthcare giant with medicines devices and consumer products. Here's the price, business snapshot, and what's worth knowing about Johnson & Johnson in July 2026.
Johnson & Johnson (JNJ) is a large, diversified healthcare company operating across pharmaceuticals, medical devices and consumer health products. With a market capitalisation of about $462.11 billion, it mixes steady cash-generative consumer brands with higher-growth prescription medicines and device franchises. Investors often watch J&J for its scale, research and development pipeline, global reach and long record of dividend payments, but the company also faces patent expiries, regulatory scrutiny, litigation risk and competition that can affect earnings. Financial performance may be influenced by new product approvals, M&A activity and macroeconomic conditions. This summary is general, educational information only and not personal advice — investing carries risk and past performance is not a reliable guide to future results. Consider consulting a financial professional about suitability for your circumstances.
Why It’s Moving
JNJ Faces Downside Pressure as Investors Reprice a Premium Defensive Name
- Analysts are still flagging valuation risk even as Johnson & Johnson retains a premium reputation, which matters because a rich multiple leaves less room for error if growth slows.
- The bearish setup is being driven more by expectations than by a fresh operating shock; with Wall Street still debating fair value, any sign of softer margin or pipeline momentum can weigh on the shares.
- JNJ’s defensive profile and strong profitability continue to support the stock, but the market is focusing on whether those strengths are already priced in, which is why downside concerns remain in the conversation.
JNJ Faces Downside Pressure as Investors Reprice a Premium Defensive Name
- Analysts are still flagging valuation risk even as Johnson & Johnson retains a premium reputation, which matters because a rich multiple leaves less room for error if growth slows.
- The bearish setup is being driven more by expectations than by a fresh operating shock; with Wall Street still debating fair value, any sign of softer margin or pipeline momentum can weigh on the shares.
- JNJ’s defensive profile and strong profitability continue to support the stock, but the market is focusing on whether those strengths are already priced in, which is why downside concerns remain in the conversation.
When is the next earnings date for Johnson & Johnson (JNJ)?
Johnson & Johnson’s next earnings report is expected on July 15, 2026, before the market opens. It will cover Q2 2026. The company has not always formally confirmed the date, but its reporting pattern has pointed to mid-July.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Johnson & Johnson's stock, with a target price suggesting potential growth.
Financial Health
Johnson & Johnson is performing well with strong revenue and profits, showing solid financial stability.
Dividend
Johnson & Johnson's dividend yield of 1.96% is decent, providing a reliable income stream for investors. If you invested $1000, you would be paid $19.60 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
AbbVie
Abbvie is a research-based biopharmaceutical company that develops and markets advanced therapies to address complex medical conditions.
ASTRAZENECA PLC
AstraZeneca is a global biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing innovative medicines.
AMGEN INC
Amgen is a global biotechnology company that focuses on discovering, developing and commercializing treatments for unmet medical needs.
Baskets Featuring JNJ
Blue-Chip Tech Stocks (After Buffett's Apple Regret)
Warren Buffett has publicly regretted selling Apple shares too early, indicating Berkshire Hathaway would buy more if prices drop significantly. This creates a unique moment to explore value-oriented tech stocks and supply chain partners that might present better current entry points.
Published: 2 April 2026
Explore BasketSemiconductor Patent Disputes (Foundry Market Impact)
GlobalFoundries has launched a major patent infringement lawsuit against Tower Semiconductor to protect its proprietary manufacturing technologies. This legal dispute underscores the growing importance of intellectual property enforcement in the competitive semiconductor sector, creating opportunities for rival foundries and IP-focused tech firms.
Published: 27 March 2026
Explore BasketDefensive Equities | Risks in a Slowing Labour Market
After the U.S. economy unexpectedly shed 92,000 jobs in February, investors are seeking shelter from the resulting market volatility. This collection features resilient, non-cyclical companies that historically maintain their value and offer stability during periods of economic deceleration.
Published: 9 March 2026
Explore BasketBiotech Patent Dispute Explained (BioNTech vs Moderna)
BioNTech is suing Moderna for patent infringement over its next-gen COVID-19 vaccine, escalating the legal rivalry between the two biotech leaders. This dispute creates a potential opening for other vaccine developers to gain a competitive edge while the giants are locked in a legal battle.
Published: 20 February 2026
Explore BasketFed Division: Fortress Balance Sheets Explained
The Federal Reserve is showing a rare public division on whether to raise, lower, or hold interest rates, creating uncertainty for the markets. This theme focuses on investing in companies with strong financial health that are better equipped to handle the market volatility resulting from unpredictable monetary policy.
Published: 19 February 2026
Explore BasketBlue-Chip Stocks Rally Beyond 50K Mark in 2025
The Dow Jones Industrial Average's historic breach of the 50,000 mark highlights a powerful rebound in the market, led by blue-chip stocks. This event signals a potential investment opportunity in established companies within the financial and industrial sectors that are demonstrating strength and stability.
Published: 7 February 2026
Explore BasketFlight to Safety Assets | Fed Uncertainty Overview
A landmark Supreme Court case is set to determine whether the president can fire a Federal Reserve governor, placing the central bank's political independence at a critical juncture. This event could spur market volatility, potentially benefiting safe-haven assets and defensive stocks that investors turn to in times of uncertainty.
Published: 21 January 2026
Explore BasketU.S. Drug Manufacturing | Multi-Billion Investment Push
Johnson & Johnson is the latest major drugmaker to lower U.S. prices in exchange for tariff exemptions, joining a broad industry trend. This government-led initiative is sparking a multi-billion dollar investment wave into domestic manufacturing, creating a significant opportunity for companies supporting the U.S. pharmaceutical supply chain.
Published: 10 January 2026
Explore BasketDrug Pricing Power | Major Pharma Stocks 2025
Following plans by major drugmakers to raise prices on hundreds of medications, the pharmaceutical industry is showcasing its significant pricing power. This development highlights an investment opportunity centered on established pharmaceutical companies capable of translating market dominance into revenue growth.
Published: 2 January 2026
Explore BasketWhy You’ll Want to Watch This Stock
Diversified revenue base
Pharmaceuticals, devices and consumer products spread revenue sources, which can smooth cycles — though divisions face different risks and growth prospects.
R&D and pipeline
A strong research pipeline can drive future growth if approvals succeed, but clinical setbacks or regulatory delays can weigh on returns.
Global footprint
Sales across many markets provide scale and resilience, yet global regulation, litigation and supply-chain risks can affect performance.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
